Suki vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 56)
Suki logo

Suki

ChallengerHealthcare Tech

AI Clinical Documentation

Suki ambient AI scribe serves 400+ health systems (4x growth in 2024), generates $1,223/month incremental revenue per provider; raised $168M including $70M Series D and Zoom Ventures (2024).

AI VisibilityBeta
Overall Score
C56
Category Rank
#164 of 596
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
60
Perplexity
61
Gemini
59

About

Suki is an AI-powered healthcare technology company founded in 2017 by Punit Soni (ex-Google/Motorola VP), headquartered in Redwood City, California. Its AI scribe listens to clinician-patient conversations and auto-generates structured notes, coding suggestions, and clinical orders. Raised $168M total including a $70M Series D (October 2024) and Zoom Ventures investment (January 2025).

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

56
Overall Score
81
#164
Category Rank
#17
74
AI Consensus
71
stable
Trend
stable
60
ChatGPT
80
61
Perplexity
75
59
Gemini
77
51
Claude
86
54
Grok
85

Key Details

Category
AI Clinical Documentation
General
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Suki
AI Clinical Documentation

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.